Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Pharmaceutical company reports 2005 second quarter financial results
August 15th, 2005
MedImmune, Inc., (MEDI) announced that total revenues for the 2005 second quarter were $88 million, including a 10% increase in sales of Synagis (palivizumab) in the U.S. to $43 million. Worldwide sales of Synagis were $51 million in the 2005 second quarter, while worldwide sales of Ethyol (amifostine) totaled $23 million and Cytogam (cytomegalovirus immune globulin intravenous (human)) totaled $11 million. MedImmune's quarterly results are heavily impacted by the seasonal use of two of its four marketed products, Synagis and FluMist (influenza virus vaccine live, intranasal), both of which are prescribed to help prevent serious respiratory viruses...
Source: Pharma Business Week (2005-08-15)
|
